Key facts
- US regulators are increasing scrutiny on clinical trials conducted in China.
- Analysts believe this could threaten China's biotech advantage.
- Concerns include data integrity and potential delays in drug approvals.
Increased scrutiny from US regulators on clinical trials conducted in China poses a potential threat to the country's burgeoning biotech industry, according to analysts. The heightened attention, particularly concerning data integrity and compliance with international standards, could slow down the development and approval processes for Chinese pharmaceutical companies seeking to access global markets.
China's biotech sector has seen significant growth in recent years, driven by government support and a large domestic market. However, concerns about the reliability of data from trials conducted there have led to a more cautious approach from international regulatory bodies. This could force Chinese companies to conduct more trials in other regions or face longer timelines for drug approvals.